PhaseBio Pharmaceuticals, Inc.
OTC: PHASQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jonathan P. Mow MBA
- Employees
- 60
- Headquarters
- Malvern, United States
- IPO year
- 2018
- Website
- https://phasebio.com
Loading PHASQ…
Loading profile data…Frequently asked questions about PHASQ
What does PhaseBio Pharmaceuticals, Inc. (PHASQ) do?
PhaseBio Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical enterprise, with a primary focus on developing and bringing to market innovative therapeutic solutions for cardiovascular ailments. Its leading drug candidate, bentracimab (PB2452), is a reversal agent designed to counteract the effects of the antiplatelet medication t...
Where does PHASQ trade?
PhaseBio Pharmaceuticals, Inc. (PHASQ) trades on the Other OTC.
What sector is PHASQ in?
PhaseBio Pharmaceuticals, Inc. (PHASQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of PhaseBio Pharmaceuticals, Inc.?
Jonathan P. Mow MBA is the chief executive officer of PhaseBio Pharmaceuticals, Inc. (PHASQ).
Where is PhaseBio Pharmaceuticals, Inc. headquartered?
PhaseBio Pharmaceuticals, Inc. is headquartered in United States.
Does PHASQ pay a dividend?
PhaseBio Pharmaceuticals, Inc. (PHASQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PHASQ go public?
PhaseBio Pharmaceuticals, Inc. (PHASQ) completed its initial public offering in 2018.